The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions ...

We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.

Fintel reports that on November 7, 2024, Baird upgraded their outlook for McKesson (NYSE:MCK) from Neutral to Outperform. ...

Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...

McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...

Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company ...

Operator Ladies and gentlemen, welcome to McKesson's second quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn ...

As of fiscal year-end 2024, McKesson had a cash and cash equivalents balance of $4.6 billion with an outstanding debt balance of $5.6 billion. Roughly one third of its debt is due to mature over the ...

McKesson Medical-Surgical, one of the largest medical supplies distributors in the country, is a subsidiary of Irving-based ...